About OcellO B.V.
OcellO is an innovative biotech company offering CRO services for the drug discovery industry that can significantly improve the efficiency of lead development. OcellO excels in the development of clinically relevant in vitro human micro-tissue models that can be used for the screening and profiling of small molecules and biologics. The analysis of these models, many of which use patient-derived material, is enabled by OcellO’s unique high throughput 3D imaging and phenotypic profiling technology. As well as providing measurements of cell growth and viability, phenotypic profiling allows the measurement of more complex biology that better correlates with clinical endpoints. Furthermore, compounds with the optimum therapeutic profile or optimum target specific profile can be selected to enable a better ranking of compounds at early stage in the drug development process. At OcellO we believe that sound collaboration and cutting edge science can speed up selection and development of clients lead compounds.
OcellO’s role within suppresSTEM
OcellO’s role within the suppresSTEM project is to develop high content screening assays for a panel of approximately 50 patient-derived colorectal cancer organoid lines developed within the consortium, validating these for bispecific antibody drug screening. OcellO will screen libraries of bispecifics in the organoid panel to identify antibodies with the optimum activity AND selectivity against selected cancer targets. The profile of oncogenic mutations in colorectal cancer has a profound effect on the morphology of the organoids. Similarly, inhibiting oncogenic pathways disrupts these aberrant morphologies. OcellO’s screening technology captures the morphology signatures of each bispecific antibody treatment, allowing these to be compared and ranked on both activity and specificity. Together with it’s consortium partners, OcellO will identify an optimum set of bispecific antibody leads for further clinical development.